Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 04, 2018 08:30 ET | Source: Insmed, Inc.

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BRIDGEWATER, N.J., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
November 08, 2018 08:30 ET | Source: Insmed, Inc.

Insmed Announces Changes to its Board of Directors

—Seasoned Pharmaceutical Executive Elizabeth McKee Anderson Appointed as New Director— —Donald Hayden, Jr. Steps Down as Chairman After 13 Years of Distinguished Service— —Chief Executive Officer...
November 06, 2018 08:30 ET | Source: Insmed, Inc.

Insmed to Present at Three November Conferences

BRIDGEWATER, N.J., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
October 30, 2018 07:30 ET | Source: Insmed, Inc.

Insmed Reports Third Quarter 2018 Financial Results and Provides Business Update

—Quarter Highlighted by U.S. FDA Approval of ARIKAYCE® (amikacin liposome inhalation suspension), Followed by Immediate Launch— BRIDGEWATER, N.J., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Insmed...
October 23, 2018 08:30 ET | Source: Insmed, Inc.

Insmed to Host Third Quarter 2018 Financial Results Conference Call on Tuesday, October 30, 2018

BRIDGEWATER, N.J., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...
October 11, 2018 08:30 ET | Source: Insmed, Inc.

Insmed Presents New Data at IDWeek 2018 and CHEST Annual Meeting Enhancing the Understanding of MAC Lung Disease and Treatment with ARIKAYCE® (amikacin liposome inhalation suspension)

BRIDGEWATER, N.J., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...
October 04, 2018 16:30 ET | Source: Insmed, Inc.

Insmed Extends Patent Protection in Japan to 2033

BRIDGEWATER, N.J., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...
October 01, 2018 08:00 ET | Source: Insmed, Inc.

Insmed to Present at Two October Conferences

BRIDGEWATER, N.J., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...
September 28, 2018 17:58 ET | Source: Insmed, Inc.

Insmed Announces FDA Approval of ARIKAYCE® (amikacin liposome inhalation suspension), the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease in Adult Patients with Limited or No Alternative Treatment Options

—Commercial availability expected in early Q4 2018— —Conference call scheduled for today at 6:15 PM ET— BRIDGEWATER, N.J., Sept. 28, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a...
September 17, 2018 08:00 ET | Source: Insmed, Inc.

Pivotal Phase 3 Data from CONVERT Study of ALIS in Patients with Treatment-Refractory NTM Lung Disease Caused by MAC Published in American Journal of Respiratory and Critical Care Medicine

--As previously reported, study met primary endpoint of culture conversion (p<0.0001)-- --ALIS under FDA Priority Review with PDUFA action date of September 28, 2018-- BRIDGEWATER, N.J., Sept. ...

Next Page keyboard_arrow_right